Compare Comcast Corporation (CMCSA) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comcast Corporation vs ResMed Inc. — how do they compare? Comcast Corporation trades at $25.46 (market cap $91.02B), while ResMed Inc. trades at $225 (market cap $32.61B). The key difference: Comcast Corporation is far larger — about 2.8× ResMed Inc.'s market cap, and Comcast Corporation pays the higher dividend (5.15%). Which is the better fit depends on your goals.
| CMCSA | RMD | |
|---|---|---|
Market Cap | $91.02B | $32.61B |
Sector | Media | Health |
52-Week High | $32.50 | $293.73 |
52-Week Low | $21.92 | $182.82 |
Enterprise Value | $173.74B | $31.97B |
Dividend Yield | 5.15% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Comcast (CMCSA) trades at $25.35, up 0.6% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.04 versus $0.97 expected, driven by wireless growth and Peacock profitability. Recent news highlights expansion of high-speed internet services and strategic initiatives like the NBCUniversal spinoff. Fundamentals show robust cash flow generation, with 2025 operating cash flow at $33.64 billion, and attractive valuation metrics including a P/E of 8.22 and EV/EBITDA of 5.09.
The outlook for CMCSA is positive, supported by analyst consensus with a $27.78 price target and 55.74% buy ratings. Investment opportunities include the potential upside from the NBCUniversal separation and sustained dividend payments. Key risks involve competitive pressures in broadband, theme park volatility, and integration challenges from corporate restructuring. The stock offers value with solid fundamentals but faces execution risks in a dynamic media landscape.
ResMed (RMD) trades at $226.00, up 2.7% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats, with Q4 2026 revenue growing 9% to $1.5 billion and non-GAAP EPS rising 16% to $2.95. Fundamentals show robust profitability with 26.94% net margin and 24.27% ROE, though weak 2027 revenue guidance has tempered sentiment.
Outlook remains positive with analyst consensus target of $235 offering 4% upside, but risks include ventilator sales suspension and cost pressures. The stock's current valuation at 21.56 P/E appears reasonable given strong cash flow generation and consistent dividend payments, making it attractive for growth-oriented healthcare investors despite near-term guidance concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
